Transcriptional control: an essential component of cancer gene therapy strategies?
The therapeutic index of cancer gene therapy approaches will, at least in part, be dictated by the spatial and temporal control of expression of the therapeutic transgenes. Strategies which allow precise control of gene transcription are likely to play a crucial role in the future pre-clinical and clinical development of gene therapy. In this review, we discuss these issues as they relate to tissue and tumor specific promoters. In addition, the exciting opportunities offered by the development of regulated gene expression systems using small molecules, radiation and heat are reviewed. It is realistic to expect that the future offers the prospect of amalgamating elements of a number of these different systems in a co-ordinated gene delivery approach with the potential to increase the efficacy and reduce the toxicity of treatment.
Harrington
K J
KJ
Molecular Medicine Program, Guggenheim 1836, Mayo Clinic, 200 1st Street SW, Rochester, MN 55902, USA.
Linardakis
E
E
Vile
R G
RG
D000494:Allosteric Regulation; D002272:Carcinoembryonic Antigen / Q000235:genetics / Q000502:physiology; D019281:Dimerization; D015972:Gene Expression Regulation, Neoplastic; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D014442:Monophenol Monooxygenase / Q000235:genetics / Q000502:physiology; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy; D017430:Prostate-Specific Antigen / Q000235:genetics / Q000502:physiology; D014158:Transcription, Genetic; D000509:alpha-Fetoproteins / Q000235:genetics / Q000502:physiology
D002272:Carcinoembryonic Antigen; D000509:alpha-Fetoproteins; D014442:Monophenol Monooxygenase; D017430:Prostate-Specific Antigen